Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

CRISPR Therapeutics AG

CRSP

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of CRISPR Therapeutics AG. A complete text table follows the diagram.

CRISPR Therapeutics Pipeline Flow

A gene-editing therapeutics pipeline remains the operating story, with limited grant and revenue activity.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001193125-26-204188
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

CRISPR Therapeutics reports $1.458M of total revenue, consisting of license and grant revenue; the development pipeline remains qualitative.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
CRISPR Therapeutics AG revenue	1	$1.5M	$1.458M reported quarterly revenue
License revenue	2	$1M	Reported license revenue
Grant revenue	2	$0.5	Reported grant revenue

Financial flows · Millions of USD
From	To	Value
CRISPR Therapeutics AG revenue	License revenue	$1M
CRISPR Therapeutics AG revenue	Grant revenue	$0.5